These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27813703)

  • 1. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.
    Desai SN; Pezzoli L; Alberti KP; Martin S; Costa A; Perea W; Legros D
    Hum Vaccin Immunother; 2017 Mar; 13(3):579-587. PubMed ID: 27813703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future cholera vaccines.
    Shaikh H; Lynch J; Kim J; Excler JL
    Vaccine; 2020 Feb; 38 Suppl 1():A118-A126. PubMed ID: 31879125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?
    Clemens J; Holmgren J
    Curr Top Microbiol Immunol; 2014; 379():231-58. PubMed ID: 24402712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global oral cholera vaccine use, 2013-2018.
    Pezzoli L;
    Vaccine; 2020 Feb; 38 Suppl 1(Suppl 1):A132-A140. PubMed ID: 31519444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of and challenges for cholera vaccines in Africa.
    von Seidlein L; Jiddawi M; Grais RF; Luquero F; Lucas M; Deen J
    J Infect Dis; 2013 Nov; 208 Suppl 1():S8-14. PubMed ID: 24101650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving immunization approaches to cholera.
    Saha A; Rosewell A; Hayen A; MacIntyre CR; Qadri F
    Expert Rev Vaccines; 2017 Mar; 16(3):235-248. PubMed ID: 27805467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice.
    Fakoya B; Sit B; Waldor MK
    J Bacteriol; 2020 Nov; 202(24):. PubMed ID: 32540930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges.
    Deen J; Holmgren J; Clemens JD
    Lancet Infect Dis; 2022 Oct; 22(10):e292-e298. PubMed ID: 35533702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach.
    Sundaram N; Schaetti C; Merten S; Schindler C; Ali SM; Nyambedha EO; Lapika B; Chaignat CL; Hutubessy R; Weiss MG
    BMC Public Health; 2016 Jan; 16():36. PubMed ID: 26762151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral cholera vaccines and their impact on the global burden of disease.
    Wierzba TF
    Hum Vaccin Immunother; 2019; 15(6):1294-1301. PubMed ID: 30183486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis.
    Lopez AL; Deen J; Azman AS; Luquero FJ; Kanungo S; Dutta S; von Seidlein L; Sack DA
    Clin Infect Dis; 2018 Jun; 66(12):1960-1971. PubMed ID: 29177437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
    Baik YO; Choi SK; Olveda RM; Espos RA; Ligsay AD; Montellano MB; Yeam JS; Yang JS; Park JY; Kim DR; Desai SN; Singh AP; Kim IY; Kim CW; Park SN
    Vaccine; 2015 Nov; 33(46):6360-5. PubMed ID: 26348402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The history of OCV in India and barriers remaining to programmatic introduction.
    Mogasale V; Kanungo S; Pati S; Lynch J; Dutta S
    Vaccine; 2020 Feb; 38 Suppl 1():A41-A45. PubMed ID: 31982258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy, demand, management, and costs of an international cholera vaccine stockpile.
    Maskery B; DeRoeck D; Levin A; Kim YE; Wierzba TF; Clemens JD
    J Infect Dis; 2013 Nov; 208 Suppl 1():S15-22. PubMed ID: 24101640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings.
    Hsiao A; Desai SN; Mogasale V; Excler JL; Digilio L
    Bull World Health Organ; 2017 Apr; 95(4):303-312. PubMed ID: 28479625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.
    Terrinoni M; Nordqvist SL; Löfstrand M; Nilsson F; Källgård S; Sharma T; Lebens MR; Holmgren J
    Vaccine; 2023 May; 41(21):3347-3357. PubMed ID: 37085452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges for programmatic implementation of killed whole cell oral cholera vaccines for prevention and control of cholera: a meta-opinion.
    Chatterjee P; Kanungo S; Dutta S
    Expert Opin Biol Ther; 2018 Sep; 18(9):983-988. PubMed ID: 30107757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholera vaccine: new preventive tool for endemic countries.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2012 May; 8(5):682-4. PubMed ID: 22634452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vibrio cholerae: lessons for mucosal vaccine design.
    Bishop AL; Camilli A
    Expert Rev Vaccines; 2011 Jan; 10(1):79-94. PubMed ID: 21162623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO.
    Chaignat CL; Monti V
    J Health Popul Nutr; 2007 Jun; 25(2):244-61. PubMed ID: 17985828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.